Sub. S. B. No. 250 As Passed by the House

Senators Coughlin, Harris, Mumper, Fedor, Fingerhut, Goodman, Schuler, Randy Gardner, Carey, Miller, Mallory, Amstutz, Dann, Hottinger, Roberts, Robert Gardner, Hagan, Jordan, Schuring, Wachtmann, Armbruster, Spada, Austria, White

Representatives White, Fessler, Blasdel, Combs, Hollister, Hoops, Kearns, Martin, Olman, Reidelbach, Schneider, Slaby, G. Smith, S. Smith, Barrett, Beatty, Cirelli, DeBose, Harwood, Price, Yates, Allen, Aslanides, Boccieri, Book, Brown, Buehrer, Calvert, Carano, Carmichael, Chandler, Clancy, Daniels, DeGeeter, Domenick, Driehaus, C. Evans, D. Evans, Flowers, Gibbs, Gilb, Grendell, Hagan, Hartnett, Hughes, Key, Latta, Mason, Miller, Niehaus, Otterman, T. Patton, Perry, Raga, Reinhard, Schaffer, Schlichter, Schmidt, Setzer, Skindell, D. Stewart, J. Stewart, Taylor, Wagner, Walcher, Webster, Widener, Widowfield, Willamowski, Woodard

A BILL

To enact sections 5.2228 and 101.38 of the Revised 1
Code to designate May as Ohio Cystic Fibrosis 2
Awareness Month and to create the Ohio Cystic 3
Fibrosis Legislative Task Force to advise the 4
State of Ohio on issues pertaining to the care and 5
treatment of individuals with cystic fibrosis. 6

BE IT ENACTED BY THE GENERAL ASSEMBLY OF THE STATE OF OHIO:

       Section 1. That sections 5.2228 and 101.38 of the Revised 7
Code be enacted to read as follows: 8

       Sec. 5.2228. The month of May is designated as "Ohio Cystic 9
Fibrosis Awareness Month" to increase public awareness of the 10
disease, including its causes and health effects and to encourage 11
and support research to develop effective medical therapies. 12

       Sec. 101.38. (A) As used in this section, "relative" means a 13
spouse, parent, parent-in-law, sibling, sibling-in-law, child, 14
child-in-law, grandparent, aunt, or uncle. 15

        (B) There is hereby created the Ohio cystic fibrosis 16
legislative task force to study and make recommendations on issues 17
pertaining to the care and treatment of individuals with cystic 18
fibrosis. The task force shall study and make recommendations on 19
the following issues: 20

       (1) Use of prescription drug and innovative therapies under 21
the program for medically handicapped children established under 22
section 3701.023 of the Revised Code and the program for adults 23
with cystic fibrosis administered by the department of health 24
under division (G) of that section; 25

       (2) Screening of newborn children for the presence of genetic 26
disorders, as required under section 3701.501 of the Revised Code; 27

       (3) Any other issues the task force considers appropriate. 28

       (C) The task force shall consist of the following members, 29
each with the authority to vote on matters before the task force: 30

        (1) Three members of the senate: two appointed by the 31
president of the senate from the majority party and one appointed 32
by the minority leader of the senate; 33

       (2) Three members of the house of representatives: two 34
appointed by the speaker of the house of representatives from the 35
majority party and one appointed by the minority leader of the 36
house of representatives; 37

        (3) Three members, at least two of whom have been diagnosed 38
with cystic fibrosis or are relatives of individuals who have been 39
diagnosed with cystic fibrosis, appointed by the president of the 40
senate; 41

        (4) Three members, at least two of whom have been diagnosed 42
with cystic fibrosis or are relatives of individuals who have been 43
diagnosed with cystic fibrosis, appointed by the speaker of the 44
house of representatives. 45

       Initial members shall be appointed not later than sixty days 46
after the effective date of this section. 47

        (D) Each member of the task force shall serve a one-year term 48
that ends on the same day of the same month as did the term that 49
it succeeds. Members may be reappointed. 50

        (E) A vacancy shall be filled in the same manner as the 51
original appointment. Any member appointed to fill a vacancy 52
occurring prior to the expiration date of the term for which the 53
member's predecessor was appointed shall hold office as a member 54
for the remainder of that term. 55

        A member shall continue in office subsequent to the 56
expiration date of the member's term until a successor takes 57
office or until a period of sixty days has elapsed, whichever 58
occurs first. 59

        (F) Members of the task force shall elect a chair to serve a 60
term of one year. A vacancy of the chair position shall be filled 61
by election. 62

        (G) Members of the task force shall receive no compensation, 63
except to the extent that serving as a member is part of the 64
individual's regular duties of employment and except for the 65
reimbursement of expenses that may be provided under division (H) 66
of this section. 67

       (H) The task force may solicit and accept grants from public 68
and private sources. Grant funds may be used to reimburse members 69
for expenses incurred in the performance of official task force 70
duties and to pursue initiatives pertaining to the care and 71
treatment of individuals with cystic fibrosis. 72

        (I) A majority of the members of the task force constitutes a 73
quorum for the conduct of task force meetings. 74

Section 1. That sections 5.2228 and 101.38 of the Revised	7
Code be enacted to read as follows:	8

Sec. 5.2228. The month of May is designated as "Ohio Cystic	9
Fibrosis Awareness Month" to increase public awareness of the	10
disease, including its causes and health effects and to encourage	11
and support research to develop effective medical therapies.	12

Sec. 101.38. (A) As used in this section, "relative" means a	13
spouse, parent, parent-in-law, sibling, sibling-in-law, child,	14
child-in-law, grandparent, aunt, or uncle.	15

(B) There is hereby created the Ohio cystic fibrosis	16
legislative task force to study and make recommendations on issues	17
pertaining to the care and treatment of individuals with cystic	18
fibrosis. The task force shall study and make recommendations on	19
the following issues:	20

(1) Use of prescription drug and innovative therapies under	21
the program for medically handicapped children established under	22
section 3701.023 of the Revised Code and the program for adults	23
with cystic fibrosis administered by the department of health	24
under division (G) of that section;	25

(2) Screening of newborn children for the presence of genetic	26
disorders, as required under section 3701.501 of the Revised Code;	27

(C) The task force shall consist of the following members,	29
each with the authority to vote on matters before the task force:	30

(1) Three members of the senate: two appointed by the	31
president of the senate from the majority party and one appointed	32
by the minority leader of the senate;	33

(2) Three members of the house of representatives: two	34
appointed by the speaker of the house of representatives from the	35
majority party and one appointed by the minority leader of the	36
house of representatives;	37

(3) Three members, at least two of whom have been diagnosed	38
with cystic fibrosis or are relatives of individuals who have been	39
diagnosed with cystic fibrosis, appointed by the president of the	40
senate;	41

(4) Three members, at least two of whom have been diagnosed	42
with cystic fibrosis or are relatives of individuals who have been	43
diagnosed with cystic fibrosis, appointed by the speaker of the	44
house of representatives.	45

Initial members shall be appointed not later than sixty days	46
after the effective date of this section.	47

(D) Each member of the task force shall serve a one-year term	48
that ends on the same day of the same month as did the term that	49
it succeeds. Members may be reappointed.	50

(E) A vacancy shall be filled in the same manner as the	51
original appointment. Any member appointed to fill a vacancy	52
occurring prior to the expiration date of the term for which the	53
member's predecessor was appointed shall hold office as a member	54
for the remainder of that term.	55

A member shall continue in office subsequent to the	56
expiration date of the member's term until a successor takes	57
office or until a period of sixty days has elapsed, whichever	58
occurs first.	59

(F) Members of the task force shall elect a chair to serve a	60
term of one year. A vacancy of the chair position shall be filled	61
by election.	62

(G) Members of the task force shall receive no compensation,	63
except to the extent that serving as a member is part of the	64
individual's regular duties of employment and except for the	65
reimbursement of expenses that may be provided under division (H)	66
of this section.	67

(H) The task force may solicit and accept grants from public	68
and private sources. Grant funds may be used to reimburse members	69
for expenses incurred in the performance of official task force	70
duties and to pursue initiatives pertaining to the care and	71
treatment of individuals with cystic fibrosis.	72

(I) A majority of the members of the task force constitutes a	73
quorum for the conduct of task force meetings.	74